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Abstract
Emerging evidence suggests microRNAs (miRNAs) may play an important role in explaining
variation in stroke risk and recovery in humans, yet there are still few longitudinal studies
examining the association between whole blood miRNAs and stroke. Accounting for multiple
testing and adjusting for potentially confounding technical and clinical variables, here we
show that whole blood miR-574-3p expression was significantly lower in participants with
chronic stroke compared to non-cases. To explore the functional relevance of our findings,
we analyzed miRNA-mRNA whole blood co-expression, pathway enrichment, and brain tis-
sue gene expression. Results suggest miR-574-3p is involved in neurometabolic and
chronic neuronal injury response pathways, including brain gene expression of DBNDD2
and ELOVL1. These results suggest miR-574-3p plays a role in regulating chronic brain and
systemic cellular response to stroke and thus may implicate miR-574-3p as a partial media-
tor of long-term stroke outcomes.
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Introduction
Stroke—ischemic stroke and hemorrhagic stroke—remains a leading cause of mortality and
long-term disability worldwide.[1] Treatment efficacy and functional outcome rely heavily on
early detection as well as understanding contributors to observed clinical variation in the
weeks and years after stroke onset. Biological risk factors leading up to an acute stroke and
multiple signaling cascades triggered throughout the brain after stroke influence the balance
between neuropathological and neuroprotective processes. However, the majority of these
pathways are not yet elucidated.
MicroRNAs (miRNAs) are a class of small (approximately 22 nucleotides), endogenous,
non-coding RNA that regulate post-translational gene expression by altering mRNA tran-
scripts.[2] Non-coding RNA networks are critical for molecular responses to disease-related
genetic and environmental exposures, and the importance of miRNAs in cerebrovascular dis-
ease is emerging. MicroRNAs exist in neurons and other cells of the central nervous system
and can be released by these cells into extracellular spaces. Due to pragmatic differences in
accessibility, circulating miRNAs may be more clinically relevant than miRNAs derived
directly from the central nervous system. MicroRNAs can be detectable in plasma, a predomi-
nantly extracellular miRNA source, and whole blood, a cellular miRNA source with cells like
peripheral blood mononuclear cells. Whereas whole blood miRNAs primarily reflect miRNA
expression of these cells, whole-blood-derived miRNA expression profiles likely also reflect
important interactions between brain pathological processes and systemic factors, such as vas-
cular inflammation or environmental exposures.[3] Much of this work is isolated to animal
models and relatively small incipient stroke cohorts, thus the molecular mechanisms underly-
ing many differentially expressed miRNAs remain unclear.[4, 5] Identifying and validating
latent biomarkers to study these pathways is ideally undertaken with the use of a large, deeply
phenotyped, longitudinal study with participants at risk of developing stroke. In the Framing-
ham Heart Study (FHS), one of the oldest and closely monitored observational community-
based cohorts in the United States, several plasma and whole blood miRNAs were associated
with age,[6] cancer,[7, 8] cardiovascular disease,[9, 10] and cardiometabolic risk factors.[11]
One recent FHS study identified 6 plasma-derived extracellular miRNAs associated with
stroke.[12] To clarify the relationship between whole blood miRNAs and cerebrovascular dis-
ease, we tested the hypothesis that whole-blood-derived miRNA expression levels would be
associated with stroke in a sample of FHS participants.
Materials and methods
Study design
FHS is a community-based family study that was initiated in 1948 and has since enrolled three
generations of participants.[13, 14] For the present investigation, we focused on the Offspring
cohort, who are children of the Original cohort or the spouses of Original cohort children.[13]
The Offspring cohort participants enrolled in 1971 and are evaluated about every 4 to 8 years.
All participants provided informed consent and the methods were carried out in accordance
with the examination protocols approved by the Boston University Medical Center Institu-
tional Review Board.
We examined miRNA cross-sectional and prospective associations with the two most com-
mon types of stroke worldwide, ischemic stroke and hemorrhagic stroke; subarachnoid hem-
orrhage was excluded from the present study given substantially different pathophysiology,
age of onset, course of treatment, and outcomes.[15, 16] In FHS, a minority of incident strokes
are hemorrhagic stroke, thus stroke cases in our study sample largely represent ischemic
Whole blood microRNA expression associated with stroke
PLOS ONE | https://doi.org/10.1371/journal.pone.0219261 August 8, 2019 2 / 15
present study confirm that they had no special
access privileges in requesting data which other
researchers would not have.
Funding: This research was supported by
P30AG10161, R01AG15819, R01AG17917,
R01AG30146, R01AG36836, U01AG32984, and
U01AG46152 to the Rush Alzheimer’s Disease
Center; N01-HC 25195, HHSN268201500001I, and
75N92019D00031 to the FHS; NS017950,
UH2NS100605, AG049505, AG052409,
AG054076, AG049607, and AG059421 to SS;
T32NS048005, AG057760, and the Robert
Katzman Research Training Fellowship in
Alzheimer’s and Dementia Research Cosponsored
by the American Academy of Neurology, the
American Brain Foundation, and the Alzheimer’s
Association to JS. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
stroke.[17] Stroke severity was classified by neurological deficits found on examination during the
acute stroke presentation and was further classified into four categories: none (no deficit), mild
(deficit in visual, motor, sensory, or language domains, but without functional impairment), mod-
erate (deficit requiring assistance in one domain), and severe (deficit requiring assistance in at
least two domains).[18] Full details regarding the FHS stroke surveillance protocol, including
diagnosis, classification, and severity assessment were published previously.[17]
Data are available on BioLINCC and access can be requested via the BioLINCC website
(https://biolincc.nhlbi.nih.gov/home/). A summary of available data and links to request data
for the Framingham Heart Study Offspring Cohort are available at https://biolincc.nhlbi.nih.
gov/studies/framoffspring/?q=framingham%20heart%20study. The Religious Orders Study
and Rush Memory and Aging Project third-party datasets analyzed during the current study
are available in the Accelerating Medicines Partnership for Alzheimer’s Disease (AMP-AD)
Target Discovery Consortium data portal. These datasets are available upon request and can
be accessed at doi:10.7303/syn2580853. Our results are reported in accordance with STROBE
guidelines.[19]
MicroRNA expression profiling
Full details of FHS miRNA expression profiling and quality control have been described previ-
ously.[20] In brief, whole blood from fasting morning samples were collected from Offspring
participants who attended exam cycle 8 (2005–2008). A total of 346 miRNAs were profiled
using quantitative real-time polymerase chain reaction (qRT-PCR) encompassing all commer-
cially available TaqMan chemistry-based miRNA assays in the Gene Expression Core Labora-
tory at the University of Massachusetts Medical School. QRT-PCR reactions were performed
using a high-throughput instrument (BioMark; Fluidigm, San Francisco, CA). The FHS
Systems Approach to Biomarker Research in Cardiovascular Disease Initiative Steering Com-
mittee reviewed all quality control measures. As in prior experiments showing excellent repro-
ducibility using the BioMark dynamic array platform in conjunction with multiplexed reverse
transcriptase reactions for miRNA profiling, we did not encounter cross-contamination with
this platform.[9] For replicates, >95% of data points had coefficients of variation <10% (mean
~4%). MicroRNA expression was quantified using cycle threshold (Ct), where higher Ct values
represent lower microRNA expression levels. MicroRNAs with a Ct value of 27 or higher were
set as missing. A total of 257 miRNAs were expressed in at least 30% of samples and used in
the current analysis. We adjusted for batch effects in regression models and did not perform
normalization on raw Ct values.
MicroRNA and mRNA co-expression analysis
Our group analyzed mRNA co-expression in secondary analysis to understand post-transla-
tional miRNA gene expression regulation in stroke. The details of mRNA expression profiling
have been previously described.[20] The Affymetrix Human Exon 1.0 ST array was used to
quantify mRNA expression levels of 17,873 unique transcripts from whole blood RNA using
the same participant samples that were collected for miRNA expression profiling. The associa-
tion between microRNA and mRNA expression was assessed by linear mixed effects modelling
adjusted for age, sex, and technical covariates, including isolation batch, RNA concentration,
RNA quality, and 260/280 ratio (defined as the ratio of absorbance at 260 and 280nm mea-
sured with spectrophotometer). To address the potential for false positive error with multiple
comparisons, we used Bonferroni correction to define statistical significance as P<2.8x10-6
(0.05/17873). The enrichment of biological pathways were performed by WebGestalt,[21] and
the KEGG pathways were interrogated.[22]
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Statistical analysis
We separated the analysis between chronic stroke and incident stroke given expected differ-
ences in underlying pathophysiologic processes leading to an acute stroke and the multiple sig-
naling cascades triggered throughout the brain and systematically after stroke. For derivation
of analytic samples see Fig 1.
In cross-sectional analysis, chronic stroke was defined as those who had a stroke before
RNA collection, which occurred at exam 8. In prospective analysis, incident stroke was defined
as those who developed stroke after RNA collection at exam 8. For chronic stroke analyses,
because miRNA was collected after stroke, we used linear mixed effect models to examine the
association of prior stroke with miRNA expression profiles, where stroke status was used as
the exposure and each miRNA was used as the dependent variable. Meanwhile for incidence
analyses, because miRNA was collected before stroke, we used Cox proportional hazards mod-
els with robust sandwich estimators for time-to-stroke to examine the prospective association
of miRNA expression with future stroke. The miRNA was used as the exposure and time-to-
stroke was used as the dependent measure. Censoring factors were death before new-onset
stroke and, if no report of stroke, last time of follow-up through December 31st, 2013.
Whereas miRNA expression can be dramatically altered in response to stroke, the implica-
tions of associated risk factors are often not taken into account.[23] To address this limitation,
our study included miRNA profiles of individuals from different age groups with risk factor
heterogeneity and adjusted statistical models for age, sex, and potentially confounding clinical
variables: systolic blood pressure, hypertension treatment, diabetes, previous cardiovascular
disease, atrial fibrillation, and smoking.[24] To account for factors related to RNA processing,
we additionally adjusted analyses for isolation batch, RNA quality, concentration, and 260/280
ratio. Using Bonferroni correction, we defined statistical significance as P<1.9x10-4 (0.05/257
miRNAs) to account for potential false positive error from multiple testing.
Fig 1. Flow diagram of analytic sample used for analysis.
https://doi.org/10.1371/journal.pone.0219261.g001
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Results
The characteristics of 2495 FHS Offspring participants in the study sample are shown in
Table 1.
The study sample was 55% women and had mean age 66 years (range from 40 to 92 years).
Our cohort included middle-age to older adults with a modest burden of cardiovascular dis-
ease risk factors commonly reflected in community-based samples. A total of 55 participants
had stroke prior to the RNA collection and, afterwards, an additional 80 participants devel-
oped stroke. The mean time from stroke to miRNA collection was 7.8 years (range 0.4 to 34.5
years). The mean time from miRNA collection to incident stroke was 3.2 years (range 0.1 to
7.5 years). Mean follow-up time after miRNA collection at exam 8 was 9.4 years (range 0.1 to
10.8 years). Seven of the 25 participants with severe stroke included in the analysis died within
10 days of their stroke. A total of 526 Offspring participants who attended exam 8 were
excluded from the analytic sample because they did not have miRNA profiled (due to no
agreement for DNA or RNA research, failure of lab experiment, or other technical factors); of
these 526 excluded participants, 23 had prior stroke.
As shown in Table 2, one miRNA was significantly associated with chronic stroke among
257 miRNAs: miR-574-3p (P = 2.6x10-6).
Fig 2 illustrates the effect size for this association.
No other miRNAs among the tested transcripts reached the significance cutoff after adjust-
ment for multiple testing (P<1.9x10-4). Table 3 shows the top results for incident stroke; no
miRNAs showed significant differences after Bonferroni correction, including miR-574-3p
(Beta = 0.03, SE = 0.05, P = 0.49).
In our secondary analyses, we excluded participants with hemorrhagic stroke (n = 1) to
assess potential confounding effects and the result was the same (P = 5.8x10-6 for miR-574-3p).
Table 1. Clinical characteristics of participants.
Variable No Stroke (n = 2360) Chronic Stroke (n = 55) Incident Stroke (n = 80)
Age, years 66±9 73±9 73±8
Men, n (%) 1051 (45%) 31 (56%) 40 (50%)
Body mass index, kg/m2 28±5 28±5 29±5
Systolic blood pressure, mm Hg 128±17 131±19 135±15
Diastolic blood pressure, mm Hg 74±10 68±9 72±10
Current smoking, n (%) 203 (9%) 6 (11%) 2 (3%)
Chronic myocardial infarction, n (%) 110 (5%) 9 (16%) 7 (9%)
Chronic heart failure, n (%) 61 (3%) 5 (9%) 3 (4%)
Chronic diabetes mellitus, n (%) 367 (16%) 23 (42%) 19 (24%)
Antihypertensive treatment, n (%) 1118 (48%) 44 (78%) 51 (65%)
Total cholesterol, mg/dL 186±37 174±40 179±38
Hyperlipidemia treatment, n (%) 1034 (44%) 35 (64%) 43 (54%)
Chronic atrial fibrillation, n (%) 156 (7%) 10 (18%) 14 (18%)
Stroke severitya, n (%)
None - 14 (25%) 4 (5%)
Mild - 34 (62%) 42 (53%)
Moderate - 7 (13%) 9 (11%)
Severe - - 25 (31%)
Data are presented as means ± standard deviation or number (percentage).
aFor stroke severity: none = no deficit; mild = deficit present in visual, motor, sensory, or language domains, but without functional impairment; moderate = deficit
requiring assistance in one domain; severe = deficit requiring assistance in at least two domains.
https://doi.org/10.1371/journal.pone.0219261.t001
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Our findings remained similar when accounting for the potential confounding effects of medi-
cations commonly used after stroke (aspirin, warfarin, and atorvastatin),[25] and miRNA
expression profile variance over time after acute stroke by additionally adjusting for the time
interval from stroke to miRNA collection; the time interval used for non-cases was 0 years (S1
Table). To assess the potential inverse effects between miRNAs and stroke, we tested the associ-
ation by treating miRNA expression as the exposure and stroke as the dependent variable. MiR-
574-3p remained the most significant miRNA associated with chronic stroke (P = 1.0x10-4, see
S2 Table).
To identify potential targets of miR-574-3p, our group tested the association of miR-574-3p
expression with gene expression in whole blood. A total of 1063 genes were significantly asso-
ciated with miR-574-3p (P<2.8x10-6). The top 20 genes are shown in S3 Table. To investigate
the potential function of these 1063 genes, we identified the top 10 pathways enriched with
these genes as shown in S4 Table.
We also examined the enrichment of miR-574-3p-associated genes among predicted miR-
574-3p targets. The predicted targets were downloaded from the PITA database.[26] Thirty-
four genes were predicted as targets of miR-574-3p. Among them, six were significantly associ-
ated with miR-574-3p in whole blood, including ATPIF1, CLTC, FOSL2, KIAA1033, RXRA,
and SRF, representing a 2.7-fold enrichment of predicted targets (Fisher’s exact test P = 0.03).
Given that different tissues could have different gene expression patterns, we studied the
association of miR-574-3p expression with gene expression in brain tissue using Religious
Orders Study and Rush Memory and Aging Project data.[27, 28] As shown in S5 Table, the
expression of DBNDD2 and ELOVL1 in brain tissue was significantly associated with miR-
574-3p expression. ELOVL1 also showed significant association with miR-574-3p in whole
blood.
Discussion
Our study examined the association of 257 whole-blood-derived miRNAs with stroke in a
community-based sample of men and women. Adjusting for age, sex, technical factors, and
potentially confounding clinical variables, we identified one miRNA—miR-574-3p—for which





Average expression (Ct) Association resultsa
Cases Non-Cases Beta SE P-valueb
miR_574_3p 53 2383 12.72 10.51 1.81 0.38 2.6E-06
miR_483_3p 24 793 22.13 23.68 -1.41 0.40 5.0E-04
RNU48_b2 54 2407 4.25 3.24 0.31 0.10 2.3E-03
miR_28_5p 54 2397 14.55 12.13 0.47 0.19 1.1E-02
miR_320b 53 2417 11.30 9.22 0.44 0.18 1.6E-02
RNU48_a2 54 2396 4.32 3.48 0.21 0.09 1.7E-02
U6_snRNA_a1 51 2313 8.92 11.13 -0.57 0.25 2.6E-02
RNU48_b1 54 2405 4.24 3.47 0.21 0.09 2.7E-02
miR_324_3p 54 2386 11.69 10.27 0.39 0.18 2.9E-02
miR_625_3p 47 2358 15.15 15.48 -0.66 0.31 3.1E-02
Abbreviations: Ct, Cycle threshold.
aModel fully adjusted for age, sex, technical factors, and potentially confounding clinical variables (systolic blood pressure, hypertension treatment, diabetes, previous
CVD, atrial fibrillation, and smoking).
bBonferroni P-value cutoff = 0.05/257 miRNAs = 1.9E-4
https://doi.org/10.1371/journal.pone.0219261.t002
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expression was downregulated in individuals who experienced a stroke before miRNA sam-
pling. The observed association suggests miR-574-3p may play a role in regulating long-term
brain and systemic cellular pathophysiologic changes triggered after stroke. Whole blood miR-
NAs may also be implicated in stroke pathogenesis, though we did not observe significant
associations between the whole blood miRNA transcripts tested and future stroke, including
miR-574-3p.
Among previous studies of smaller incipient acute-stroke cohorts, circulating whole-blood-
derived miR-574-3p was also reported as downregulated in the setting of acute stroke.[29] Our
results agree with Sepramaniam et al.’s findings[29] and add to the extant research by further
supporting the role of miR-574-3p as an important gene regulator in cerebrovascular disease.
[12, 30]
Circulating miRNAs are released by cardiac and endothelial cells in stress states and have
been associated with cardiovascular disease, suggesting that functional specificity is responsi-
ble for the cellular expression of unique miRNAs.[6, 9–11] In whole blood, cardiovascular
Fig 2. Volcano plot of effect sizes for associations between whole blood miRNA expression profiles and chronic stroke in
Framingham Offspring participants.
https://doi.org/10.1371/journal.pone.0219261.g002
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disease has been linked to miRNA transcriptional patterns (e.g., co-expression pattern disrup-
tion for B-cell-centered immune function in cases of coronary heart disease).[31] As reviewed
by Small et al.,[32] various cardiovascular disease settings have been associated with specific
changes in miRNA profiles, including myocardial remodeling which typically involves cardio-
myocyte hypertrophy (miR-1, miR-21, miR-23, miR-133, miR-208a), cardiomyocyte apoptosis
and regeneration (miR-195, miR-199a, miR-320), aberrant cardiac conduction (miR-1), inter-
stitial fibrosis (miR-21, miR29, miR-133a), restenosis (miR-21, miR-145, miR-221), and angio-
genesis (miR-221, miR-222, miR-210, miR-126, miR-17-92). More recently, McManus et al.
showed significant associations between cardiometabolic risk factor clustering and whole-
blood-derived levels of miR-197-3p, miR-328, miR-505-5p, and miR-145-5p.[11] Whereas
whole blood miR-574-3p has been associated with promoting vascular smooth muscle cell
growth in the progression of coronary artery disease,[33] as expected, whole blood miR-574-
3p in our sample was significantly associated with prevalent cardiovascular disease
(P = 1.4x10-5) in post-hoc analysis. Prevalent cardiovascular disease was defined as reported
presence or history of diseases related to atherosclerosis at the time of blood collection for
miRNA profiling, which includes coronary heart disease, myocardial infarction, coronary
insufficiency, intermittent claudication, and congestive heart failure. In a prior FHS study,
plasma miR-574-3p was unassociated with cardiovascular disease (i.e., coronary heart disease).
[12] In examining other diseases, plasma miR-574-3p levels have been associated with various
forms of cancer.[34, 35] However, the time course and extent that whole blood miRNA expres-
sion profiles reflect cerebrovascular events remain unclear. MicroRNAs can regulate genes
central in thrombogenicity and neuroinflammation, including some implicated directly in
stroke pathogenesis.[23, 36] In cell models, miR-574-3p downregulation was associated with
remnant-like lipoprotein acceleration of endothelial progenitor cell senescence,[37] though
miR-574-3p regulation of identified target genes has yet to be studied in cell models.
Human and animal models suggest miRNA expression profiles can vary by acute phase or
recovery phase of stroke, and the miRNA expression profiles that can be used to distinguish
between acute or recovery phase typically return to baseline levels over time.[29] In contrast to
prior work, we did not observe a significant association between other whole blood miRNAs
related with acute stroke.[29, 38–40] Beyond technical and context-dependent differences,





Average expression (Ct) Association resultsa
Cases Non-Cases Beta SE P-valueb
miR_484 80 2323 4.58 4.78 -0.58 0.21 6.4E-03
miR_29b_2_5p 78 2249 21.67 21.02 0.22 0.08 9.3E-03
miR_193b_3p 76 2308 18.23 18.90 -0.18 0.07 1.4E-02
miR_26b_5p 78 2274 18.14 16.76 0.11 0.05 1.9E-02
miR_1271_5p_b1 74 2258 18.40 18.68 -0.18 0.08 3.7E-02
let_7d_3p 37 891 21.11 22.34 -0.16 0.08 4.1E-02
miR_129_1_3p 55 1683 22.93 23.51 -0.18 0.09 4.2E-02
miR_629_3p 73 2286 18.59 19.05 -0.17 0.09 4.7E-02
miR_16_1_3p 63 1765 22.69 22.23 0.14 0.07 4.8E-02
miR_320b 80 2346 9.41 9.21 -0.20 0.10 4.9E-02
Abbreviations: Ct, Cycle threshold.
aModel fully adjusted for age, sex, and technical factors, and potentially confounding clinical variables (systolic blood pressure, hypertension treatment, diabetes,
previous CVD, atrial fibrillation, and smoking).
bBonferroni P-value cutoff = 0.05/257 miRNAs = 1.9E-4
https://doi.org/10.1371/journal.pone.0219261.t003
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disagreement between our findings and other studies may be due to differences between study
populations (e.g., Sepramaniam et al. included individuals primarily of East Asian descent).
[29] We also did not observe significant associations with the 6 plasma-derived extracellular
miRNAs linked with stroke prevalence or incidence.[12] Mick et al.’s study of plasma-derived
extracellular RNAs used the same FHS Offspring cohort and found that chronic stroke was
associated with 3 miRNAs (miR-877-5p, miR-124-3p, and miR-320d) and 1 small nucleolar
RNA (SNO1402), while incident stroke was associated with 3 independent miRNAs (miR-
656-3p, miR-3615, and miR-941). Our results complement this literature by examining whole-
blood-derived miRNA transcripts associated with stroke. Observed differences between
plasma and whole blood miRNA expression profiles associated with chronic stroke are consis-
tent with Shah et al.’s general observation of within-individual discordance between plasma
versus whole-blood-derived miRNA transcripts.[30]
Regarding the potential function of the 1063 genes expressed in blood associated with miR-
574-3p, many significant genes were enriched in pathways involved in non-alcoholic fatty liver
disease (P = 2.7x10-9) and Alzheimer’s disease (AD, P = 2.2x10-7), suggesting that miR-574-3p
might exert its effect through brain-related pathways, particularly neurometabolic function
and chronic response to neuronal injury given the association of miR-574-3p expression with
DBNDD2 and ELOVL1 gene expression in brain tissue. Aside from established links between
cerebrovascular disease and increased AD risk,[41] previous investigation has identified asso-
ciations between atherosclerotic cardiovascular disease outcomes (including stroke) and non-
alcoholic fatty liver disease.[42] Potential mechanisms for this association include proathero-
genic factors in hepatic steatosis, such as diabetes, hypertension, and dyslipidemia or unmea-
sured signaling factors released by the liver.[43] Another possible mechanism includes
increased inflammation in the setting of hepatic steatosis, which may be involved in early ath-
erogenesis.[44] Visceral adiposity and lipid metabolism and synthesis may also play a role. For
example, common low-density lipoprotein receptor polymorphisms have been tied to RNA
splicing efficiency in human liver, brain, and AD.[45] Among the two genes expressed in brain
tissue associated with miR-574-3p, ELOVL1 (ELOVL fatty acid elongase 1) regulates very long
chain fatty acid synthesis, particularly in the brain, and inhibiting ELOVL1 with agents like
fibrates reduces very long chain fatty acid accumulation in fibroblasts.[46] The second associ-
ated gene expressed in brain tissue was DBNDD2 (dysbindin domain containing 2). DBNDD2
encodes dysbindin, which is a protein that functions in parallel with the ubiquitin modification
system to modulate lysosome biosynthesis and protein turnover and trafficking.[47, 48]
DBNDD2 is implicated in neurodegeneration and neuronal injury as an apoptosis response
gene.[47] For example, dysbindin and dysbindin homologues like casein kinase-1 binding pro-
tein (CK1BP) are found in ubiquitinated lesions, including neurofibrillary tangles and granu-
lovacuolar degeneration bodies in AD.[48] Supporting this functional relationship, in the
present study miR-574-3p was associated with whole blood enrichment of genes more gener-
ally involved in response to genotoxic stress, such as cell hypoxia, normal vasculogenesis, and
cell cycle regulation. Relevant cellular functions in genotoxic stress response included platelet
activation, focal adhesion, regulation of actin cytoskeleton, B cell receptor signaling pathways,
and leukocyte transendothelial migration, which are implicated in molecular models of
chronic cerebrovascular disease and signaling cascades after brain ischemia.[49]
Whole blood miRNAs may regulate neuronal or glial gene expression directly or indirectly
by regulating gene expression in other tissues relevant to stroke, such as peripheral mononu-
clear cells. In the context of chronic stroke, our findings likely represent a circulating pool of
miRNAs determined by downregulated intracellular concentrations of miR-574-3p in periph-
eral mononuclear cells. Beyond regulating gene expression through translation inhibition, our
findings may be explained by increased post-transcriptional degradation of miR-574-3p.
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Moreover, observed functional associations could be attributed to cell-specific regulation from
chronic stroke-related physiological disturbances outside of the central nervous system, such
as hepatocytes.
Our results did not support an association between whole-blood-derived miRNA expres-
sion profiles and incident stroke, though this does not preclude the existence of a link between
the two.[36] For example, single nucleotide polymorphisms (SNPs) associated with stroke may
exist outside of intronic gene regions and thus may not be related to gene expression. Further-
more, the limited number of new-onset stroke cases in our sample may explain why our group
did not observe a significant association between miR-574-3p and incident stroke. Other
explanations for our incidence analysis results include bidirectional relationships between
microRNA expression levels and stroke, intermediate mechanisms, differential use of medica-
tions affecting miR-574-3p expression, and variations in stroke-related neuroinflammation
processes due to inherited or acquired changes in the cholinergic blockade of inflammation
(e.g., via common SNPs).[50, 51]
While our findings suggest miR-574-3p may be a mediator of neurometabolic and cytotoxic
stress responses to stroke, an alternative explanation for the observed associations is that miR-
574-3p may be involved in stroke pathogenesis. However, this explanation is less likely given
the present incidence analyses did not show a significant prospective association. A second
possibility is that miR-574-3p may be associated with survival; though, in post-hoc analysis
miR-574-3p was not associated with survival after stroke in our sample (P = 0.65). In testing
this association, the most significant miRNA for survival after stroke was miR-18a-5p-a1, but
it did not cross the Bonferroni significance threshold either. A third alternative for the
observed miR-574-3p association with chronic stroke is differences in stroke severity which
would have likely attenuated observed effects. Although participants with milder chronic
strokes are more likely to follow-up in cohort studies, our sample had minimal loss to follow-
up regardless of stroke severity. Other possible explanations for the observed relationship with
chronic stroke are that miR-574-3p is associated with residual confounding from a stroke
intervention, acquired or inherited individual biological differences, or other unknown mech-
anisms not included in our models.
The molecular underpinnings of cerebrovascular disease are complex, because heterotypic
SNP-miRNA-mRNA associations are disrupted by brain pathology and broader extrinsic risk
factors.[3] Although miR-574-3p was not associated with incident stroke, given prior work
suggesting miR-574-3p is a partial regulator in acute stroke and our observed association with
chronic stroke, miR-574-3p merits further exploration as a potential biomarker or treatment
target for long-term outcomes of cerebrovascular disease. Thus, larger longitudinal samples of
participants from diverse backgrounds at risk for new-onset stroke are needed.
Our study has limitations. First, FHS participants are predominantly middle-age adults of
European ancestry so the generalizability of our findings, especially to other races and ethnici-
ties or younger individuals, remains unclear. Second, given that whole blood may include
miRNA-loaded exosomes and is comprised of different cell types, the miRNA contribution of
each cell type is relevant. Our analyses were not adjusted for cell composition because whole
blood cell composition was not determined at the time miRNA was quantified. Third, low
abundance miRNAs were excluded when not present in at least 30% of samples. Finally, our
cross-sectional analysis cannot establish causality or directionality between miRNAs and stroke.
Conclusions
MiR-574-3p was associated with stroke in a community-based sample of more than 2000 par-
ticipants. The functional role and regulatory molecular mechanisms of miRNA before, during,
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and after stroke are not well understood yet investigating these mechanisms may clarify the
pathogenic or neuroprotective properties of miRNAs, inform better treatments for cerebrovas-
cular disease, and facilitate better measurement of neuropathology where direct access to tissue
for molecular analyses is desirable but not feasible. Additional studies are needed to further
verify our findings and identify other miRNAs that may serve as accessible diagnostic or thera-
peutic targets for cerebrovascular disease.
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